CoChat
Sign Up
Cited by 55Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesFerroptosis and cancer prognosis

Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis

Abdel-Rahman, O., Helbling, D., Schmidt, J., Petrausch, U., Giryes, A., Mehrabi, A., Schöb, O., Mannhart, M. +1 more·2017·Clinical Oncology
DOI 10.1016/j.clon.2016.11.007
Open this paper in CoChat — free account

Abstract

Aims We carried out a meta-analysis to determine the risk of treatment-related death associated with immune checkpoint inhibitor use in cancer patients.Materials and methods We examined data from the Medline and Google Scholar databases. We also examined original studies and review articles for cross-references. Eligible studies included randomised phase II and phase III trials of patients with cancer treated with ipilimumab, pembrolizumab; nivolumab; tremelimumab and atezolizumab. The authors extracted relevant information on participants, characteristics, treatment-related death and information on the methodology of the studies.Results After exclusion of ineligible records, 18 clinical trials were included in the analysis. The odds ratio for treatment-related death for CTLA-4 inhibitors (ipilimumab and tremelimumab) was 1.80 (95% confidence interval 1.25, 2.59; P=0.002) and for PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab and atezolizumab) was 0.63 (95% confidence interval 0.31, 1.30; P=0.22). Treated cancer seems to have no effect on the risk of treatment-related death.Conclusions Analysis of our data showed that CTLA-4 inhibitors (ipilimumab and tremelimumab) in a higher dose (10 mg/kg) seem to be associated with a higher risk of treatment-related death compared with control regimens, whereas PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab and atezolizumab) do not cause the same risk. Clinicians have to be fully aware of these differential risks and council their patients appropriately.

Integrity signals

Registry

Crossref · 10.1016/j.clon.2016.11.007

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A meta-analysis of 18 clinical trials revealed an increased risk of treatment-related mortality in patients receiving higher dose (10 mg/kg) of CTLA-4 inhibitors.

    “Furthermore, a meta-analysis of 18 clinical trials revealed an increased risk of treatment-related mortality (TRM) in patients receiving higher dose (10 mg/kg) of CTLA-4 inhibitors [146].”

    From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [146]

  • Dose-dependent adverse events of CTLA-4 blockade ranging from mild to moderate occurred in more than 70% of patients.

    “It was demonstrated that dose dependent adverse events of CTLA-4 blockade ranging from mild to moderate occurred in more than 70% of patients [146].”

    From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [146]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Abdel-Rahman, O., Helbling, D., Schmidt, J., Petrausch, U., Giryes, A., Mehrabi, A., Schöb, O., Mannhart, M., & Oweira, H.
Affiliations
  • Ain Shams University (EG)
  • Klinik Hirslanden (CH)
  • Heidelberg University (DE)
Corresponding author
Abdel-Rahman, O.
ORCID
Venue
Clinical Oncology
Publisher
Elsevier BV
Published
2017-04
Volume
29
Issue
4
Pages
218-230
ISSN
0936-6555 (ISSN-L)
DOI
10.1016/j.clon.2016.11.007
OpenAlex
W2896805387
Cited by
55
References
38
Citations by year
2026: 2 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 5 · 2020: 5 · 2019: 6 · 2018: 11 · 2017: 10 · 2013: 1
FWCI
0.91
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Ferroptosis and cancer prognosis
Keywords
immune checkpoint inhibitors, non-relapse mortality, CTLA-4 inhibitors, PD-1/PD-L1 inhibitors, ipilimumab, tremelimumab, nivolumab, pembrolizumab, atezolizumab, cancer immunotherapy, dose-dependent risk
MeSH terms
Antibodies, Monoclonal, Antineoplastic Agents, Humans, Neoplasms, Risk Assessment, CTLA-4 Antigen, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review